|
|
½Å°æ º¸È£ : ÀǾàǰ¡¤½ÃÀ塤±â¾÷ Neuroprotection - Drugs, Markets and Companies |
|
Pub Time : 2010/02 Published by : Jain Pharmabiotech |
| ¹ßÀÛÀ̳ª ½Å°æ°è ¼Õ»ó µîÀÇ ±Þ¼º Áúȯ, ½Å°æº¯¼º ÀåÇØ µîÀÇ ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ ÀÖ¾î¼ ½Å°æ º¸È£ÀÇ ¿ªÇÒ¿¡ ´ëÇØ Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ : ½Å¾à, ½ÃÀå, ±â¾÷ Alzheimer disease - new drugs, markets and companies |
|
Pub Time : 2010/02 Published by : Jain Pharmabiotech |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Ä¡·á¾à °³¹ß µ¿Çâ ¹× °ü·Ã ±â¾÷ÀÇ Á¤º¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á ¹× Áø´Ü ½ÃÀå Alzheimer's Disease Therapeutics and Diagnostics: Global Markets |
|
Pub Time : 2010/01 Published by : BCC Research |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á ¹× Áø´Ü ½ÃÀåÀÇ ÇöȲ, 2008³â ½ÃÀå µ¥ÀÌÅÍ, 2014³â±îÁöÀÇ ¼ºÀå·ü, µ¿ ½ÃÀåÀÌ Á÷¸éÇÑ °úÁ¦, °³¹ßÁßÀÎ Ä¡·áÁ¦ µ¿Çâ°ú µ¿ ½ÃÀåÀÇ ±âȸ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ, ƯÇ㠺м® µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
2014³â±îÁöÀÇ ÁßÃß ½Å°æ°è ½ÃÀå Àü¸Á : °æÇÕ È¯°æ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ¼ºÀå ±âȸ The CNS Market Outlook to 2014: Competitive landscape, pipeline analysis and growth opportunities |
|
Pub Time : 2010/01 Published by : Business Insights |
| ÁßÃß ½Å°æ°è ½ÃÀåÀÇ °³¿ä¿Í 7´ë ½ÃÀåÀÇ ½ÇÀû, ºê·£µå ¾àǰÀÇ Çã°¡ ½ÇÈ¿¿¡ µû¸¥ Á¦³×¸¯ ÀǾàǰÀÇ ´ëµÎ ¹× ½Å¾à °³¹ß µ¿Çâ, ½ÃÀå¿¡ Âü°¡ÇÏ´Â ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù. |
|
´Ù¹ß¼º °æÈÁõ : ¸®½ºÅ©¿Í ¸Þ¸®Æ®ÀÇ ºñÀ² Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs |
|
Pub Time : 2009/12 Published by : Datamonitor |
| ´Ù¹ß¼º °æÈÁõÀÇ Áø´Ü, Ä¡·á, ÀÌȯ µ¿Çâ, ½ÃÀåÀÇ ¹ÌÃæÁ· ¿ä±¸¸¦ ºÐ¼®Çϰí, 2004³âºÎÅÍ 2008³â±îÁöÀÇ ½ÇÀû, 2009³âºÎÅÍ 2018³â±îÁöÀÇ ¼¼°è 7´ë ½ÃÀåÀÇ ¹ßÀü ¿¹Ãø, ¿¬±¸ °³¹ßÀ» À§ÇÑ ±â¾÷ÀÇ Àü·« µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ½Å°æÀÚ±Ø ½ÃÀå Àü¸Á Neurostimulation - A Global Market Perspective |
|
Pub Time : 2009/11 Published by : BizAcumen, Inc. |
| ¼¼°èÀÇ ½Å°æÀÚ±Ø ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ÀÇ»çÀÇ ½Å°æÀڱؼú¿¡ ´ëÇÑ ÀÎÁöµµ ¹× ½ÃÀåÀÇ µ¿Çâ, ô¼ö½Å°æÀڱؼú, ³ú½ÉºÎÀڱؼú, õ¼ö½Å°æÀڱؼú, ¹ÌÁֽŰæÀڱؼú µîÀÇ ´Ù¾çÇÑ Á¦Ç° °³¿ä, ÁÖ¿ä ±â¾÷ÀÇ È°µ¿, °¢±¹ ½ÃÀåÀÇ µ¿Çâ µîÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù. |
|
Ç×°æ·ÃÁ¦ : ºñ°£Áú¼º Ç×°æ·ÃÁ¦°¡ °¡Á®¿À´Â ºí·Ï¹ö½ºÅÍÀÇ °¡´É¼º Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential |
|
Pub Time : 2009/10 Published by : Datamonitor |
| ÇöÀç ¹× ÇâÈÄÀÇ ¼¼°è ÁÖ¿ä 7´ë Ç×°æ·ÃÁ¦ ½ÃÀå¿¡ ´ëÇØ »ó¼¼È÷ ºÐ¼®Çϰí, 2018³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ½ÃÀå ±âȸ ¹× À§Çù, ÁÖ¿ä ±â¾÷ÀÇ È®´ë Àü·«¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¸é¿ª¿ä¹ý°ú ¹é½ÅÀÇ »õ·Î¿î ÀûÀÀ Immunotherapies and Vaccines for Nontraditional Indications |
|
Pub Time : 2009/10 Published by : Insight Pharma Reports |
| ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÀÇÁ¸Áõ, ±×¹ÛÀÇ ½Å°æ°è ÁúȯÀ» Æ÷ÇÔÇÑ ¸é¿ª¿ä¹ýÀÇ »õ·Î¿î ÀûÀÀ¿¡ ´ëÇØ Á¶»çÇϰí, °¢ Áúȯ¿¡ °üÇÑ º´Å»ý¸®ÇÐ, ¿ªÇÐ, ÇöÀçÀÇ ¾à¹°Ä¡·á µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
ÆÄŲ½¼º´ : ½ÃÀå ¼ºÀå¿¡ °øÇåÇÏ´Â ÀϺ»°ú À¯·´ Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth |
|
Pub Time : 2009/10 Published by : Datamonitor |
| ¹Ì±¹, ÀϺ», ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹ÀÇ ÆÄŲ½¼º´ ½ÃÀå ÇöÀç »óȲ°ú ÇâÈÄ µ¿Çâ, 2008³â¡2018³â±îÁöÀÇ ºê·£µå ¾àǰ, Á¦³×¸¯ ÀǾàǰ ¸ÅÃâ ¿¹Ãø, ½ÃÀåÀÇ ¼º°ø¿äÀÎ ¹× ÁÖ¿ä ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏÀ» ÀüÇØµå¸³´Ï´Ù. |
|
½Å°æ ÀÚ±Ø ¿ä¹ý - ÷´Ü ±â¼ú°ú ¼¼°è ½ÃÀå(2009¡2014³â) Neurostimulation - Advanced Technologies and Global Market (2009 - 2014) |
|
Pub Time : 2009/09 Published by : Markets and Markets |
| ¼¼°èÀÇ ½Å°æ ÀÚ±Ø ¿ä¹ý ½ÃÀåÀ» ´ë»óÀ¸·Î ±× ÇöÀç »óȲ°ú ÇâÈÄ 5³â°£ÀÇ ÇâÈÄ Àü¸Á »ê¾÷ÀÇ °úÁ¦ ¹× ÃßÁø¿äÀÎÀ» ¸é¹ÐÈ÷ °ËÁõÇÑ µ¥ÀÌÅÍ¿Í ÇÔ²² ÀüÇØµå¸³´Ï´Ù. |
|
Áß±¹ÀÇ ÁßÃ߽Űæ°è Áúȯ Ä¡·á¾à ½ÃÀå Chinese Markets for Central Nervous System Disorder Drugs |
|
Pub Time : 2009/09 Published by : Asia Market Information & Development Co. |
| Áß±¹ÀÇ ÁßÃ߽Űæ°è Áúȯ Ä¡·á¾à ½ÃÀå¿¡ ´ëÇØ Á¶»çÇϰí, Áß±¹ÀÇ °æÁ¦ µ¿Çâ, ÅõÀÚ È¯°æ, »ê¾÷ÀÇ ¹ßÀü°ú ¼ö±Þ µ¿Çâ, ¸¶ÄÉÆÃ Ã¤³Î, ÁÖ¿ä ½ÃÀå Âü°¡ ±â¾÷ ºÐ¼®, ½ÇÀû(1998³â¤ý2003³â¤ý2008³â) ¹× Àå±âÀû ¿¹Ãø(2013-2018³â), ÁÖ¿ä Á¦Á¶»çÀÇ ÇÁ·ÎÆÄÀÏÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ½Å°æº¯¼ºÁúȯ ½ÃÀå : 2009-2024³â World Neurodegenerative Diseases Market 2009-2024 |
|
Pub Time : 2009/09 Published by : Visiongain |
| ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, ´Ù¹ß¼º°æÈÁõ µîÀÇ ½Å°æº¯¼ºÁúȯ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, 2009³â ÀÌÈÄ Ãâ½Ã ¿¹Á¤ÀÎ Ä¡·á¾à µ¿Çâ°ú ½Å°æº¯¼ºÁúȯ ½ÃÀåÀÇ ¸ÅÃâ ¿¹Ãø, ½ÃÀåÁ¡À¯À², ¿¬±¸ °³¹ß µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ : °áÁ¤Àû À§Çè ºÎ´ã, È¿°ú ³ôÀº Ä¡·á¹ý Pipeline Insight: Alzheimer's Disease - The ultimate high-risk, high-reward therapy market |
|
Pub Time : 2009/08 Published by : Datamonitor |
| 2018³â±îÁöÀÇ ½ÃÀå ¿¹Ãø, ÇöÀçÀÇ ºê·£µå¾à, ¼¼°è ÁÖ¿ä ±¹°¡ÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ ȯÀÚ Áõ°¡ µ¿Çâ ¹× ¹ÙÀÌ¿À¸¶Ä¿ °³¹ßÀÇ Çʿ伺 µîÀ» ³íÀÇÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¼¶À¯±ÙÅë ½ÃÀåÀÇ ¿¹Ãø Fibromyalgia Market Forecast |
|
Pub Time : 2009/06 Published by : Datamonitor |
| ¼¼°è ÁÖ¿ä 7°³ ½ÃÀåÀÇ ¼¶À¯±ÙÅë ½ÃÀåÀ» Á¶»çÇϰí, ÇöÀç ¹× ÇâÈÄÀÇ ½ÃÀå ±Ô¸ð Á¤·®È, ÃÖ±Ù ¹× ¿¹ÃøµÇ´Â À̺¥Æ®(ƯÇãÀÇ ±âÇѸ¸·á, ½ÅÁ¦Ç° ÅõÀÔ, ±ÔÁ¦ Àΰ¡)ÀÇ ¿µÇâ, 2008-2018³âÀÇ ½ÃÀå ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ·¹º¸µµÆÄ(CAS 59-92-7) ½ÃÀå : 2009³â Levodopa (CAS 59-92-7) Market Report 2009 |
|
Pub Time : 2009/06 Published by : Merchant Research & Consulting LTD. |
| ·¹º¸µµÆÄ(CAS 59-92-7)ÀÇ °³¿ä¿Í ¾ÖÇø®ÄÉÀÌ¼Ç ºÐ¾ß ¹× ƯÇã, Á¦Á¶»ç ¹× »ó»ç¿¡ °üÇÑ Áö¿ªº° Á¤º¸, Áö¿ªº° ÇöÀçÀÇ ½ÃÀå °¡°Ý µîÀ» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
À¯·´ÀÇ ÆÄŲ½¼º´ Ä¡·á ½ÃÀå European Markets for Parkinson's Disease Therapeutics |
|
Pub Time : 2009/05 Published by : Frost & Sullivan |
| À¯·´ÀÇ ÆÄŲ½¼º´ Ä¡·á ½ÃÀåÀ» ºÐ¼®Çϰí, ½ÃÀå±âȸ, ÃÖ±ÙÀÇ ¹ßÀü, ¾àÁ¦ Ŭ·¡½º, ¼öÀÍ ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
Áß±¹ÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ ½ÃÀå Chinese Markets for Alzheimer Disease Drugs |
|
Pub Time : 2009/04 Published by : Asia Market Information & Development Co. |
| Áß±¹ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ ½ÃÀåÀÇ ÅõÀÚ È¯°æ, »ê¾÷ÀÇ ¹ßÀü, ¼ö¿ä¤ý°ø±Þ, »ê¾÷ ±¸Á¶, ½ÃÀå °æ·Î¤ýÁÖ¿ä ±â¾÷ µîÀ» »ó¼¼È÷ Á¶»çÇϰí 2003³â ¹× 2008³âÀÇ ½ÇÀû°ú 2013³â¤ý2018³âÀÇ Àå±â ¿¹ÃøÀ» ÀüÇØµå¸³´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ : 2009³âÀÇ ½ÃÀå¤ýÆÄÀÌÇÁ¶óÀΤý±âȸ Alzheimer's Disease: Markets, Pipeline and Opportunities 2009 |
|
Pub Time : 2009/04 Published by : BioPharm Reports (Technology and Markets Ltd) |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ÀÇ °³¿ä ¹× ¼¼°èÀû, Áö¿ªÀû µ¿Çâ, ÇöÀçÀÇ ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀÎ Àü·«, ºÐ¾ßÀÇ ÇâÈÄ ±âȸ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
°æµµÀÎÁö Àå¾Ö Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® Pipeline Insight: Mild Cognitive Impairment - Unlocking the potential of prodromal Alzheimer's disease and beyond |
|
Pub Time : 2009/04 Published by : Datamonitor |
| °æµµÀÎÁö Àå¾ÖÀÇ ¹ßº´ µ¿Çâ ¹× ±â¾÷¿¡ µû¸¥ ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ°í °æµµÀÎÁö Àå¾ÖÀÇ °¢Á¾ ºÎºÐ°ú °úÁ¦, ÁÖ¿ä 7°³±¹ÀÇ °æµµÀÎÁö Àå¾Ö Ä¡·áÁ¦ ¸ÅÃâ ¿¹Ãø, ÁÖ¿ä ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦ÀÇ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
±â¾ï ¹× ÀÎÁö Àå¾ÖÀÇ Ä¡·á µ¿Çâ Therapeutics for Memory and Cognition Disorders |
|
Pub Time : 2009/04 Published by : BCC Research |
| ±â¾ï Àå¾Ö ¹× ÀÎÁö Àå¾ÖÀÇ Ä¡·á µ¿Çâ°ú ÇâÈÄ Àü¸ÁÀ» Á¶»ç ºÐ¼®Çϰí, À̵é ȯÀÚÀÇ ¿øÀÎÀÌ µÇ´Â Áúº´ »óȲ, Ä¡·á¾àÀÇ ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, ½ÃÀå ¼ºÀå Àü¸Á, ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎ, ÁÖ¿ä ±â¾÷ÀÇ È°µ¿ ¹× ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ´Ù¹ß¼º °æÈÁõ ½ÃÀå : 2009-2024³â The Global Multiple Sclerosis Market 2009-2024 |
|
Pub Time : 2009/03 Published by : Visiongain |
| ¼¼°è ´Ù¹ß¼º °æÈÁõ ½ÃÀåÀÇ ¸ÅÃâ ¿¹Ãø°ú ½Å¾à °³¹ß µ¿Çâ, ÁÖ¿ä Ä¡·á¾àÀÇ °³¿ä¿Í Âü°¡±â¾÷ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
´Ù¹ß¼º°æÈÁõ Ä¡·á ½ÃÀå : °æ±¸¾àÀÇ ±âȸ Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs |
|
Pub Time : 2009/03 Published by : Koncept Analytics |
| ¼¼°è ´Ù¹ß¼º°æÈÁõ ½ÃÀåÀÇ ¼ö¿ä¿Í ÀáÀçÀû ±âȸ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, ȯÀÚÀÇ ÀÌȯÀ² ¹× Ä¡·á¹ý°ú ÇÔ²² ¾÷°è Âü°¡±â¾÷ÀÇ °³¿ä¿Í ºñÁî´Ï½º Àü·« µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ ½ÃÀå Global Alzheimer Drugs Market: An Analysis |
|
Pub Time : 2009/03 Published by : Koncept Analytics |
| ¼¼°èÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ ¹Ì±¹, Áß±¹À» Áß½ÉÀ¸·Î ½ÃÀå Á¶»ç¸¦ ÇÏ¿© ½ÃÀåÀÇ Æ¯Â¡¿¡ °üÇÑ µ¿Çâ°ú ±âȸ µîÀ» °ËÁõÇÏ°í °æÇÕÀÇ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏ ¹× ½ÃÀåÀÇ Àü¸ÁÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
2013³â±îÁöÀÇ ÅðÇ༺ ½Å°æÁúȯ ½ÃÀå ¿¹Ãø Neurodegenerative Market Forecast to 2013 |
|
Pub Time : 2009/02 Published by : Cutting Edge Information |
| ÅðÇ༺ ½Å°æÁúȯ Ä¡·á¾àÀÇ °³¹ß µ¿Çâ°ú °æÇÕ, Àü·«Àû Æ÷Áö¼Å´×°ú ÇÔ²² ½ÃÀå ¼ºÀå±âȸ, ÀÓ»ó½ÃÇè µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ ½Å°æ ÀÚ±Ø ÀåÄ¡ ½ÃÀå : 2009³â US Markets for Neurostimulation Devices 2009 |
|
Pub Time : 2009/02 Published by : Millennium Research Group |
| ¹Ì±¹ÀÇ ½Å°æ ÀÚ±Ø ÀåÄ¡ ½ÃÀåÀº 2008³â 10¾ï ´Þ·¯°¡ ³Ñ´Â ±Ô¸ð¿¡ ´ÞÇß½À´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ ¹ÙÀÌ¿À¸¶Ä¿ : 2009³â Alzheimer's Disease Biomarkers, 2009 |
|
Pub Time : 2009/01 Published by : BioPharm Reports (Technology and Markets Ltd) |
| ÃÖ±Ù ¾ËÃ÷ÇÏÀ̸Ӻ´¿ëÀ¸·Î °³¹ßµÇ°í ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇØ Æ÷°ýÀûÀ¸·Î ºÐ¼®Çϰí ÇöÀçÀÇ °³¹ß µ¿Çâ, »õ·Î¿î ¾àÁ¦ Ç¥Àû µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
Requip(¸®Å¢)ÀÇ »ç·Ê ¿¬±¸ : ¶óÀÌÇÁ »çÀÌŬ °ü¸®¿Í ¼º¼÷ ºê·£µåÀÇ ÀçȰ¼ºÈ Requip Case Study: Life Cycle Management - Reinvigorating a Mature Brand |
|
Pub Time : 2008/12 Published by : Best Practices, LLC |
| GlaxoSmithKline»çÀÇ ÆÄŲ½¼º´ Ä¡·áÁ¦¡¸Requip(¸®Å¢)¡¹ÀÇ RLS(ÇÏÁöºÒ¾È ÁõÈıº) Ä¡·áÁ¦·Î¼ÀÇ ÀçȰ¼ºÈ Àü·«¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ°í ¼º¼÷ Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ °ü¸®, Àçºê·£µù¿¡ µû¸¥ ¼º°ø, ¸ÅÃâ Ȱ¼ºÈÀÇ ¹æ¹ý µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
½Å°æº¯¼º Áúȯ : 4´ë ÁúȯÀ» À§ÇÑ Â÷¼¼´ë Ä¡·áÁ¦ °³¿ä Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders Overview |
|
Pub Time : 2008/12 Published by : Insight Pharma Reports |
| ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ÇåÆÃÅϺ´, ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ 4´ë ½Å°æº¯¼º ÁúȯÀ» À§ÇÑ Â÷¼¼´ë °³·® ¾àÁ¦¿¡ ´ëÇØ ¼Ò°³Çϰí, °¢ ÁúȯÀÇ °³¿ä ¹× Ä¡·á¹ý, ¿¬±¸ °³¹ß µ¿Çâ, °³¹ßÁßÀÎ ¾à 150°³ ÈÇÕ¹°¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
°£Áú : ½Å¾à Ãâ½Ã¿¡ µû¸¥ ÇâÈÄÀÇ ½ÃÀå ¹ßÀü Forecast Insight: Epilepsy - Future market upgrade following new drug launches |
|
Pub Time : 2008/12 Published by : Datamonitor |
| ÃÖ±Ù °£Áú ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Â ¿äÀΰú ±×¿¡ ´ëÇÑ Àü·«, 7´ë ½ÃÀåÀÇ 2017³â±îÁöÀÇ ÁÖ¿ä ºê·£µå, Á¦³×¸¯¾àÀÇ ¸ÅÃâ ¿¹Ãø, ¿ÀÇǴϾ𠸮´õÀÇ °ßÇØ µîÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ ¼ö¸é Àå¾Ö ½ÃÀå : 2008³â Sleep Disorders - US - November 2008 |
|
Pub Time : 2008/11 Published by : Mintel International Group Ltd, |
| ¼ö¸é Àå¾Ö Ä¡·áÁ¦ÀÇ ¸ÅÃâ ÃËÁøÀÎÀÚ, ½ÃÀåÀÇ °æÇÕ, ¹Ì±¹ÀÇ ¼¼´ë, ÀÎÁ¾, ¼Òµæº° Ä¡·áÁ¦ ÀÌ¿ë µ¿Çâ, ¸¶ÄÉÅÍÀÇ ±âȸ ¹× ºê·£µå ½ÇÀû µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
ÇÏÁö ºÒ¾È ÁõÈıº Stakeholder Opinions: Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail |
|
Pub Time : 2008/11 Published by : Datamonitor |
| ÇöÁ¸ÇÏ´Â ÇÏÁö ºÒ¾È ÁõÈıº ½ÃÀåÀ» öÀúÈ÷ ºÐ¼®Çϰí 2004³âºÎÅÍ 2007³â±îÁö ¹Ì±¹, ÀϺ», À¯·´ ÁÖ¿ä 5°³±¹ÀÇ °¢ ¾àÁ¦ Á¦Ç° ÆÇ¸Å¾× ¹× ¼ö·® Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù. |
|
½Å°æ°è Èñ¼Ò Áúº´ - Á¦3ºÎ : ÁßÁõ ±Ù¹«·ÂÁõ Pipeline Insight: Orphan Diseases in Neurology - Part III: Myasthenia Gravis |
|
Pub Time : 2008/11 Published by : Datamonitor |
| ÇâÈÄÀÇ ÁßÁõ ±Ù¹«·ÂÁõ ½ÃÀå¿¡ ´ëÇÑ ºÐ¼®, ÃÖÁ¾ ´Ü°è ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦ÀÇ ¼öÀÍ ¿¹Ãø µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå US Neuropathic Pain 2008, 4th Edition |
|
Pub Time : 2008/09 Published by : WWMR, Inc. |
| ¹Ì±¹ÀÇ ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀ» Á¶»ç ºÐ¼®Çϰí, ÀǾàǰ Ŭ·¡½º ¹× ÄÁµð¼Çº° ¹Ì±¹½ÃÀå Ãß°è ¹× ¿¹Ãø, ÅëÁõÀÇ °¢Á¾ À¯Çüº° ¹ßº´ÀÚ¼ö, ȯÀÚÀα¸ ¿¹Ãø, °¢Á¾ Ä¡·á¹æ¹ý, ÃÖ±ÙÀÇ Ãâ½Ã Á¦Ç°¤ýÀΰ¡ Á¦Ç°¤ýÆÄÀÌÇÁ¶óÀÎ ÁßÀÎ Á¦Ç° µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
ÁßÃ߽Űæ°è ¹ÙÀÌ¿À¸¶Ä¿ ±â¾÷, Á¦Ç°, Àü¸Á CNS Biomarkers Players, products and prospects |
|
Pub Time : 2008/08 Published by : Espicom Business Intelligence |
| ¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Àüü ¹× ÁßÃ߽Űæ°è ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» Á¶»ç ºÐ¼®Çϰí, ½ÃÀå Àüü¤ýºê·£µåº°¤ý±â¾÷º° ¼öÀͽÇÀû ¹× ¿¹Ãø, °ü·Ã±â¼ú, ÁÖ¿ä ±â¾÷°ú R&D Ȱµ¿, »ê¾÷ÀÇ ÁÖ¿ä °è¾à¤ý°Å·¡¤ýÁ¦ÈÞ, ÁÖ¿ä ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
ÁßÃ߽Űæ°è(CNS) Drug Discoveries µ¿Çâ : ¾ËÃ÷ÇÏÀ̸Ӻ´ CNS Drug Discoveries: Alzheimer's Disease |
|
Pub Time : 2008/08 Published by : Espicom Business Intelligence |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ °¢Á¾ Ä¡·áÁ¦ °³¹ß µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí Ãâ½ÃµÈ ÁÖ¿ä Á¦Ç°ÀÇ »óȲ ¹× ¸Å»ó ½ÇÀû¡¤¿¹Ãø, °³¹ßÁßÀÎ Á¦Ç°ÀÇ »óȲ ¹× ÇâÈÄ ¸Å»ó ¿¹Ãø, ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ȯÀÚ¿¡ °üÇÑ °¢Á¾ µ¥ÀÌÅÍ, Á¦Ç°¡¤±â¾÷ÀÇ °æÇÕ ºÐ¼® µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
ÁßÃ߽Űæ°è(CNS) Drug Discoveries : ÆÄŲ½¼º´ CNS Drug Discoveries: Parkinson's disease |
|
Pub Time : 2008/08 Published by : Espicom Business Intelligence |
| ÆÄŲ½¼º´ÀÇ °¢Á¾ Ä¡·áÁ¦ °³¹ß µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Ãâ½ÃµÈ ÁÖ¿ä Á¦Ç°ÀÇ »óȲ ¹× ¸Å»ó ½ÇÀû¡¤¿¹Ãø, °³¹ßÁßÀÎ Á¦Ç°ÀÇ »óȲ ¹× ÇâÈÄ ¸Å»ó ¿¹Ãø, ÆÄŲ½¼º´°ú ȯÀÚ¿¡ °üÇÑ °¢Á¾ µ¥ÀÌÅÍ, Á¦Ç°¡¤±â¾÷ °æÇÕ ºÐ¼® µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
CNS Áúȯ Ä¡·áÁ¦ÀÇ ¾à°¡¡¤»óȯ µ¿Çâ SPECIAL REPORT: Key Pricing and Reimbursement Trends for CNS Drugs |
|
Pub Time : 2008/07 Published by : Decision Resources, Inc. |
| ¼¼°è ÁÖ¿ä ±¹°¡¡¤Áö¿ª CNS(ÁßÃ߽Űæ°è) Áúȯ Ä¡·áÁ¦ÀÇ ¾à°¡¡¤»óȲ µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí ÁÖ¿ä ¾àÁ¦ Ŭ·¡½ºÀÇ ¾à°¡ º¯µ¿, ±¹°¡º° »óȯ °ü·Ã µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
½Å°æ°úÀÇ Áø´Ü - ¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿¿¡ ÀÇÇÑ ¼öÀÍ È®´ë Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenues |
|
Pub Time : 2008/07 Published by : Datamonitor |
| ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ´Ù¹ß¼º °æÈÁõ, °£Áú, ÆíµÎÅë, ºÒ¸éÁõ, ÇåÆÃÅϺ´, ±ÙÀ§Ã༺ Ãø»ö°æÈÁõÀÇ ½Å°æÇÐÀû »óÅ¿¡¼ÀÇ ÁÖ¿ä ¹ÙÀÌ¿À¸¶Ä¿ °³¿ä, ½Å°æÇÐÀû Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿ÀÇ »ó¾÷Àû ¼º°ø¿¡ ÇÊ¿äÇÑ ¿äÀÎÀÇ Æ¯Á¤, ¾ËÃ÷ÇÏÀ̸Ӻ´ Áø´Ü Çâ»ó¿¡ µû¸¥ ¼öÀÍ °¡´É¼º µî¿¡ ´ëÇØ ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
ºê·£µå¿Í Àü·« : ¾ËÃ÷ÇÏÀ̸Ӻ´ Brands & Strategies: Alzheimer's Disease |
|
Pub Time : 2008/06 Published by : Decision Resources, Inc. |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ ½ÃÀåÀÇ µ¿Çâ°ú ½ÃÀå¿¡ Âü°¡ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ °³¿ä, ÁÖ¿ä ºê·£µå¿¡ ´ëÇÑ ÀÇ»çÀÇ °ßÇØ¿Í 2012³â±îÁöÀÇ ¸ÅÃâ ¿¹ÃøÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
½Å°æº´Áõ¼º ÅëÁõ : UCBÀÇ Vimpat¿¡ ÀÇÇÑ °æÇÕ Àü¸Á Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players |
|
Pub Time : 2008/06 Published by : Datamonitor |
| ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀÇ ÇöȲ ¹× Àå·¡ µ¿Çâ°ú ÇÔ²² ¹Ì±¹, EU 5°³±¹ ¹× ÀϺ»ÀÇ ºê·£µå ÀǾàǰ, Á¦³×¸¯ ÀǾàǰ, Ãâ½Ã°¡ ÀÓ¹ÚÇÑ ¾àÁ¦ÀÇ 2017³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Áø´Ü ¹× Ä¡·á µ¿Çâ Diagnostic and Therapeutic Trends in Alzheimer's Disease |
|
Pub Time : 2008/06 Published by : Technical Insights, Inc. |
| ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ Ãֽе¿ÇâÀ» ±â¼ú ¹× ¾÷°è Àü¸ÁÀÇ µÎ°¡Áö Ãø¸éÀ¸·Î ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× ÆÄŲ½¼º´ Ä¡·á ½ÃÀå Alzheimer's and Parkinson's Disease |
|
Pub Time : 2008/05 Published by : Global Industry Analysts, Inc. |
| ¼¼°è ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·á¾à, ÆÄŲ½¼º´ Ä¡·á¾à ½ÃÀåÀÇ ¹Ì±¹, ij³ª´Ù, ÀϺ», À¯·´, ±âŸ Áö¿ªº° ºÐ¼®°ú ÇöÀç±îÁöÀÇ ½ÇÀû ¹× Àå·¡ ¿¹Ãø, ´ë±â¾÷, Æ´»õ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏ µîÀ» Á¦°øÇÕ´Ï´Ù. |
|
Èñ¼ÒÁúº´ : ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ(ALS) ORPHAN DISEASE SERIES - Amyotrophic Lateral Sclerosis: Strategies for Drug Developers |
|
Pub Time : 2008/05 Published by : Decision Resources, Inc. |
| ALSÀÇ °³¿ä, ¿ªÇÐ, ÇöÀçÀÇ Ä¡·á¹ý ¹× »õ·Î¿î Ä¡·á¹ý, ALS Ä¡·áÀÇ »õ·Î¿î µ¿Çâ ¹× ÇâÈÄ Àü¸Á, ¾àÁ¦ °³¹ß ±â¾÷ÀÇ Àü·« µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¼¼°èÀÇ ÁßÃ߽Űæ°è Ä¡·á¾à ½ÃÀå CNS Therapeutics |
|
Pub Time : 2008/05 Published by : Global Industry Analysts, Inc. |
| ¼¼°è ÁßÃ߽Űæ°è Ä¡·á¾à ½ÃÀåÀÇ ¼ö¿ä ¹× µ¿Çâ, ¿¬±¸°³¹ß µ¿Çâ, ÁÖ¿ä ÁßÃ߽Űæ°è ÁúȯÀÇ °³¿ä, Á¦Ç°°³¹ß, ¼¼°è °¢±¹ÀÇ ½ÃÀå ºÐ¼® µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
ÁßÃ߽Űæ°è Á¦³×¸¯ ÀǾàǰ : 2012³â±îÁöÀÇ Àü¸Á ¹× ±âȸ CNS Generic Drugs: Prospects and Opportunities to 2012 |
|
Pub Time : 2008/04 Published by : Espicom Business Intelligence |
| ÁßÃ߽Űæ°è Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®Çϰí, ÁÖ¿ä ¾àÁ¦ÀÇ 2012³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø°ú 2015³â±îÁöÀÇ Æ¯Çã ½ÇÈ¿ µ¿Çâ ¹× °æÇÕ µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
Target Product Profile : °æµµÀÎÁöÀåÇØÀÇ ¾àÁ¦ °³¹ß Target Product Profiles: Physician Insights on Key Attributes - Mild Cognitive Impairment, A therapy that improves ADAS-cog score from baseline at 12 months for the treatment of mild cognitive impairment. |
|
Pub Time : 2008/03 Published by : Decision Resources, Inc. |
| °æµµÀÎÁöÀåÇØÀÇ º´ÀΡ¤º´Å»ý¸®¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ°í °æµµÀÎÁöÀåÇØ Ä¡·áÁ¦ÀÇ ¾àÁ¦ °³¹ß ȯ°æ, Àǻ簡 ÁÖ¸ñÇÏ´Â ¼Ó¼º, ÀÇ»çÀÇ Ã³¹æ °áÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÓ»ó»óÀÇ ¿£µåÆ÷ÀÎÆ®, ¹ÌÃæÁ· ¿ä±¸»çÇ×, Target Product Profile¿¡ ÀÇÇÑ °¢Á¾ ¼Ó¼º¡¤¿£µåÆ÷ÀÎÆ®¿¡ ´ëÇÑ ÆÛÆ÷¸Õ½º ÁöÇ¥ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¾ËÃ÷ÇÏÀ̸Ӻ´ : ½Ã³ª¸®¿À ¿¹Ãø¿¡ ÀÇÇÑ ½ÃÀå °¡´É¼º Pipeline and Commercial Insight: Alzheimer's Disease - Scenario forecasts reveal vast market potential |
|
Pub Time : 2008/03 Published by : Datamonitor |
| ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ´ëÇÑ ÇöÀçÀÇ Ãâ½Ã ºê·£µå¿Í ÈÄ±â ÆÄÀÌÇÁ¶óÀÎ ¾àǰ, 2017³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ¼öÀÍ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÇâÈÄÀÇ ½ÃÀå µ¿Çâ ¹× ¹ÌÃæÁ· ¼ö¿ä µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
|
|